The COVID-19 epidemic has led to new sources of research funding being channeled towards emerging economies. This funding from philanthropists and global governance bodies reflects the fact that emerging economies may not see the peak of the infections for months to come and need support in effectively dealing with the consequences of the pandemic. Understanding the strategic priorities of new funding to properly assess future opportunities for drug development is key.
Cytel and Certara invite you to join us for a virtual panel discussion, bringing together highly acclaimed key opinion leaders and industry experts.
Hear world renowned speakers provide a critical overview of the New Opportunities & Implications for the Future of Drug Development in Emerging Economies.
Edward Mills, PhD, FRCP Edin, Principal Scientist, Global Health, Cytel
Craig Rayner, PharmD. President, Integrated Drug Development, Certara
James Orbinski, Dignitas International and York University
Derek Angus, REMAP-CAP and Crown Coronation Trials, and University of Pittsburgh
Trevor Mundel, President, Global Health Division, Bill & Melinda Gates Foundation
Robin Mogg, Clinical Biostatistics Leader, Bill & Melinda Gates Medical Research Institute
• Understand the strategic priorities of philanthropic enterprise within global health as it relates to COVID-19;
• Receive an overview of expedited clinical development in emerging economies;
• Harness existing pharmaceutical supply chains in emerging economies;
• Obtain insight into vaccine and drug distribution in emerging economies.